Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience

G Ital Dermatol Venereol. 2020 Jun;155(3):366-367. doi: 10.23736/S0392-0488.18.06017-0. Epub 2018 Sep 20.

Authors

Marta Vernero¹, Davide G Ribaldone², Marco Astegiano³, Rinaldo Pellicano³

Affiliations

¹ Division of Gastroenterology, Department of Medical Sciences, Molinette-S. Giovanni Antica Sede Hospital, Turin, Italy.
² Division of Gastroenterology, Department of Medical Sciences, Molinette-S. Giovanni Antica Sede Hospital, Turin, Italy - davrib_1998@yahoo.com.
³ Department of General and Specialist Medicine, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy.

PMID: 30249085
DOI: 10.23736/S0392-0488.18.06017-0

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Humans
Incidence
Inflammatory Bowel Diseases / drug therapy
Male
Melanoma / epidemiology*
Middle Aged
Retrospective Studies
Skin Neoplasms / epidemiology*
Tumor Necrosis Factor Inhibitors / administration & dosage
Tumor Necrosis Factor Inhibitors / adverse effects*

Substances

Tumor Necrosis Factor Inhibitors